Literature DB >> 23053777

Depression with psychotic features in a child with SLE: successful therapy with psychotropic medications--case report.

Milica Pejovic Milovancevic1, Vladimir Miletic, Smiljka Popovic Deusic, Saveta Draganic Gajic, Dusica Lecic Tosevski.   

Abstract

Systemic lupus erythematosus (SLE) is a multisystemic, autoimmune disease of unknown etiology, which affects multiple organ systems, including the central nervous system (CNS). Neuropsychiatric manifestations are seen in 13-75% of all SLE patients, with equal frequency in children and adults. Despite a high prevalence of psychiatric manifestations, there is no consensus on the proper treatment of such cases. We report here a case of an 11-year-old girl diagnosed with a severe depressive episode with psychotic features, treated successfully with risperidone and sertraline as an adjunct to immunosuppressive therapy.

Entities:  

Mesh:

Substances:

Year:  2012        PMID: 23053777     DOI: 10.1007/s00787-012-0330-5

Source DB:  PubMed          Journal:  Eur Child Adolesc Psychiatry        ISSN: 1018-8827            Impact factor:   4.785


  19 in total

1.  Cognitive impairment in systemic lupus erythematosus: a follow-up study.

Authors:  S Carlomagno; S Migliaresi; L Ambrosone; M Sannino; G Sanges; G Di Iorio
Journal:  J Neurol       Date:  2000-04       Impact factor: 4.849

2.  Longitudinal analysis of gray and white matter loss in patients with systemic lupus erythematosus.

Authors:  Simone Appenzeller; Leonardo Bonilha; Pablo A Rio; Li Min Li; Lilan Tereza Lavras Costallat; Fernando Cendes
Journal:  Neuroimage       Date:  2006-11-16       Impact factor: 6.556

3.  Evaluation and treatment of acute psychosis in children with Systemic Lupus Erythematosus (SLE): consultation-liaison service experiences at a tertiary-care pediatric institution.

Authors:  Eyal Muscal; Tania Nadeem; Xiofan Li; Ayesha Mian; Toi Blakley Harris
Journal:  Psychosomatics       Date:  2010 Nov-Dec       Impact factor: 2.386

4.  Anti-NR2A antibody as a predictor for neuropsychiatric systemic lupus erythematosus.

Authors:  Takahisa Gono; Yasushi Kawaguchi; Hirotaka Kaneko; Katsuji Nishimura; Masanori Hanaoka; Sayuri Kataoka; Yuko Okamoto; Yasuhiro Katsumata; Hisashi Yamanaka
Journal:  Rheumatology (Oxford)       Date:  2011-01-05       Impact factor: 7.580

5.  Premorbid performance IQ deficit in schizophrenia.

Authors:  G P Amminger; M Schlögelhofer; T Lehner; S Looser Ott; M H Friedrich; H N Aschauer
Journal:  Acta Psychiatr Scand       Date:  2000-12       Impact factor: 6.392

6.  Use of aripiprazole in adolescents with a history of lupus-associated psychosis and refractory psychiatric manifestations.

Authors:  Eyal Muscal; Leng Bang; Ayesha Mian; Toi Blakley Harris
Journal:  J Psychiatr Pract       Date:  2011-05       Impact factor: 1.325

7.  Proclivity to self-injurious behavior in MRL-lpr mice: implications for autoimmunity-induced damage in the dopaminergic system.

Authors:  S Chun; R McEvilly; J A Foster; B Sakic
Journal:  Mol Psychiatry       Date:  2007-09-04       Impact factor: 15.992

Review 8.  Neurocognitive impairment in children and adolescents with systemic lupus erythematosus.

Authors:  Deborah M Levy; Stacy P Ardoin; Laura E Schanberg
Journal:  Nat Clin Pract Rheumatol       Date:  2009-02

Review 9.  MRI and the brain in systemic lupus erythematosus.

Authors:  J W Graham; W Jan
Journal:  Lupus       Date:  2003       Impact factor: 2.911

10.  Assessment of cognitive function in patients with systemic lupus erythematosus.

Authors:  D Mulherin; E Doherty; A O'Connell; B Bresnihan
Journal:  Ir J Med Sci       Date:  1993-01       Impact factor: 1.568

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.